MedPath

Epizyme, Inc.

Epizyme, Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2007-01-01
Employees
250
Market Cap
-
Website
http://www.epizyme.com

Clinical Trials

50

Active:27
Completed:12

Trial Phases

3 Phases

Phase 1:39
Phase 2:5
Phase 3:2

Drug Approvals

2

NMPA:1
FDA:1

Drug Approvals

Tazemetostat Hydrobromide Tablets

Product Name
达唯珂
Approval Number
国药准字HJ20250031
Approval Date
Mar 18, 2025
NMPA

Clinical Trials

Distribution across different clinical trial phases (46 trials with phase data)• Click on a phase to view related trials

Phase 1
39 (84.8%)
Phase 2
5 (10.9%)
Phase 3
2 (4.3%)

A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation

Phase 2
Not yet recruiting
Conditions
Follicular Lymphoma
Refractory Follicular Lymphoma
Interventions
First Posted Date
2023-10-05
Last Posted Date
2024-10-31
Lead Sponsor
Epizyme, Inc.
Target Recruit Count
55
Registration Number
NCT06068881

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

First Posted Date
2022-01-25
Last Posted Date
2023-08-15
Lead Sponsor
Epizyme, Inc.
Registration Number
NCT05205252
Locations
🇺🇸

California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States

🇺🇸

Central Care Cancer Center, Bolivar, Missouri, United States

🇺🇸

Astera Cancer Center, East Brunswick, New Jersey, United States

A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Phase 1
Terminated
Conditions
Diffuse Large B Cell Lymphoma Refractory
Diffuse Large B-Cell Lymphoma
Multiple Myeloma, Refractory
Multiple Myeloma in Relapse
Interventions
First Posted Date
2021-11-16
Last Posted Date
2025-06-22
Lead Sponsor
Epizyme, Inc.
Target Recruit Count
13
Registration Number
NCT05121103
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Astera Cancer Care, East Brunswick, New Jersey, United States

🇺🇸

Weill Cornell Medicine, New York, New York, United States

and more 5 locations

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Phase 2
Terminated
Conditions
Follicular Lymphoma
Interventions
Combination Product: Rituximab
First Posted Date
2021-02-21
Last Posted Date
2024-03-25
Lead Sponsor
Epizyme, Inc.
Target Recruit Count
5
Registration Number
NCT04762160
Locations
🇺🇸

Alabama Oncology, Birmingham, Alabama, United States

🇺🇸

Compassionate Cancer Care, Fountain Valley, California, United States

🇺🇸

USOR/Rocky Mountain Cancer Centers, Boulder, Colorado, United States

and more 14 locations

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

Phase 1
Completed
Conditions
Epithelioid Sarcoma (ES)
Hematologic Malignancy
Diffuse Large B-Cell Lymphoma (DLBCL)
Rhabdoid Tumor
All Malignancies
Follicular Lymphoma (FL)
Non-Hodgkin Lymphoma (NHL)
Renal Medullary Carcinoma
Mesothelioma
Advanced Malignancies
Interventions
First Posted Date
2020-09-03
Last Posted Date
2025-02-19
Lead Sponsor
Epizyme, Inc.
Target Recruit Count
42
Registration Number
NCT04537715
Locations
🇺🇸

California Cancer Associates for Research and Excellence, Inc. (cCARE), Encinitas, California, United States

🇺🇸

The Angeles Clinic and Research Institute, Los Angeles, California, United States

🇺🇸

Northwestern University-Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States

and more 7 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

China's NMPA Grants Conditional Approval to Tazemetostat for EZH2-Mutant Follicular Lymphoma

China's National Medical Products Administration (NMPA) has granted conditional approval to tazemetostat (Tazverik) for adult patients with relapsed or refractory EZH2-mutated follicular lymphoma who have received at least two prior systemic therapies.

China Grants Conditional Approval for Tazverik to Treat Relapsed or Refractory Follicular Lymphoma

China's National Medical Products Administration (NMPA) has conditionally approved Tazverik (tazemetostat) for adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation who have received at least two prior systemic therapies.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.